Welcome to our dedicated page for AKSO HEALTH GROUP news (Ticker: AHG), a resource for investors and traders seeking the latest updates and insights on AKSO HEALTH GROUP stock.
Akso Health Group reports developments in its China-based social e-commerce business and its expansion into healthcare equipment, medical technology, and related healthcare services. News items have covered AI-enabled medical consultation, patient support initiatives, oncology-service concepts, and early research in brain-computer interface technology, including neural sensing, AI neural decoding, and interface design.
The company’s updates also include Nasdaq listing-compliance notices, filing-status matters, and other public-company actions affecting its American depositary shares. Akso Health has stated that its BCI work has not produced human clinical trials, regulatory submissions, or related revenue.
Akso Health Group (NASDAQ: AHG) announced on April 27, 2026 the launch of a proprietary Brain-Computer Interface (BCI) R&D program. The company said it is building foundational R&D infrastructure focused on ultra-high-resolution neural sensing, real-time AI neural decoding, and next-generation interface design with patent applications pending.
Akso Health noted the program targets neuroscience, advanced therapeutics, and human-machine interaction, and that progress is subject to successful research, development, and regulatory processes.
Akso Health (NASDAQ: AHG) launched an exploratory global patient support initiative and a strategic cooperation with Nanning Duoling Research Institute on Feb 3, 2026. The program aims to coordinate medical resources to provide free in-hospital treatment plans for up to 10,000 eligible patients through an integrated "TCM practice + modern medical technology" model.
The plan connects planned radiation oncology centers, targeted drugs, and remote consultation teams, with Nanning Duoling supplying diagnostic technologies, reagents, lab testing, and expert teams. Participation is limited, phased, conditional on eligibility, institutional qualifications, regulatory requirements, and funding.
Akso Health Group (NASDAQ: AHG) announced the integration of DeepSeek's artificial intelligence technology to enhance its healthcare services. The company will utilize DeepSeek's multimodal large-scale models, deep learning frameworks, and big data processing capabilities to upgrade its AI-powered diagnosis system.
The enhanced system will integrate patient text descriptions, medical imaging, and laboratory test results to provide more accurate diagnoses and personalized treatment recommendations. AHG is also developing an AI-powered medical assistant to support doctors in retrieving patient records, analyzing similar cases, and recommending treatment plans.
The company focuses on implementing human-centric AI interactions to ensure a more natural and empathetic user experience, aiming to reduce patient anxiety and optimize consultation experiences. AHG plans to continue exploring AI applications in research and development, health management, and telemedicine.
Summary not available.
Summary not available.
Akso Health Group (NASDAQ: AHG) announced it received a notification from Nasdaq on February 28, 2023, indicating it is non-compliant with the minimum stockholders' equity requirement of $10 million. As of September 30, 2022, Akso reported approximately $9.9 million in stockholders' equity. While this notification does not immediately affect its listing, Akso has until April 14, 2023, to propose a compliance plan. If accepted, Nasdaq may grant an extension of up to 180 days, extending the compliance deadline to August 27, 2023.
Akso continues to operate within the social e-commerce and healthcare equipment sectors, previously known as Xiaobai Maimai.
Akso Health Group (NASDAQ: AHG) announced that it received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement of US$1.00 per share, effective from October 26, 2022. The company's shares had fallen below this threshold for 30 consecutive business days. Akso Health has until April 24, 2023, to regain compliance. The company is exploring options like a reverse share split but asserts that its business operations remain unaffected. Furthermore, Nasdaq accepted the company’s plan for compliance regarding the delinquent filing of its Annual Report on Form 20-F.
Akso Health Group (NASDAQ: AHG) announced it received a notification from Nasdaq on August 16, 2022, for not complying with timely filing requirements, as it has not filed its Annual Report on Form 20-F for the fiscal year ended March 31, 2022. The Company has 60 days to address this deficiency or submit a plan to regain compliance by October 17, 2022. The notification does not affect the Company's business operations. Akso Health also plans to expand into cancer therapy services, including opening 100 radiation oncology centers in the U.S.